Venetoclax (Venclexta) in combo with Obinutuzumab for CLL - Details
( Last Updated : December 2, 2020)
Obinutuzumab for CLL
NOC Status at Filing:
10 mg, 50 mg and 100 mg
Chronic Lymphocytic Leukemia (CLL)
Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible.
Pre Noc Submission:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Reimburse with clinical criteria and/or conditions
Final Recommendation Issued:
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.